Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LATS1 | O95835 | 5/20 | 0.38 |
| ▸ | LATS2 | Q9NRM7 | 3/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.31 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.31 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.31 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31491363 | 0.86 | LATS1 (0.38) | LATS1LATS2 | |
| SCHEMBL31083959 | 0.83 | LATS1 (0.43) | LATS1LATS2 | |
| SCHEMBL31491319 | 0.83 | LATS1 (0.41) | LATS1LATS2 | |
| SCHEMBL31083963 | 0.82 | LATS1 (0.41) | LATS1LATS2LMNATP53MAPT | |
| SCHEMBL31084020 | 0.81 | LATS1 (0.40) | LATS1LATS2 | |
| SCHEMBL31084006 | 0.81 | LATS1 (0.40) | LATS1LATS2 | |
| SCHEMBL31083981 | 0.81 | TRPV3 (0.44) | LATS1LATS2 | |
| SCHEMBL31083989 | 0.81 | LATS1 (0.41) | LATS1LATS2 | |
| SCHEMBL31084044 | 0.80 | LATS1 (0.39) | LATS1LATS2LMNAMAPT | |
| SCHEMBL31084098 | 0.80 | LATS1 (0.42) | LATS1LATS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025067168-A1 | AZA FUSED RING COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | 苏州爱科百发生物医药技术有限公司 | 2025-04-03 | — | — | WO | disclosed |